Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 6/20 | 0.85 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.85 |
| ▸ | AVPR1B known ✓ | P47901 | 4/20 | 0.85 |
| ▸ | OXTR | P30559 | 9/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL13775933 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL2687079 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22510 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29317578 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL14027607 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL204511 | 0.98 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | NITTO DENKO CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2762159-A1 | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | AVPR1A 2537/4885AVPR2 2753/4885AVPR1B 2666/4885 |
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | TAP1, TAP2, MICA | AVPR1A 2605/4885AVPR2 2700/4885AVPR1B 2593/4885 |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MUC1 | AVPR1A 1412/4885AVPR2 1367/4885AVPR1B 1274/4885 |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | ERBB2, EGFR, ERBB3 | AVPR1A 4049/4885AVPR2 3619/4885AVPR1B 3727/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | AVPR1A 977/4885AVPR2 1202/4885AVPR1B 1248/4885 |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | TAP1, TAP2, MICA | AVPR1A 2537/4885AVPR2 2753/4885AVPR1B 2666/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | AVPR1A 2605/4885AVPR2 2700/4885AVPR1B 2593/4885 |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | BAX, GZMB, BCL2 | AVPR1A 4810/4885AVPR2 4682/4885AVPR1B 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.